Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2012.

Net loss for the first quarter of 2012 was $7.1 million, or $0.36 per share, compared with a net loss of $3.2 million, or $0.30 per share, for the first quarter of 2011.  Common shares used in calculating basic and diluted earnings per share were 19,607,483 for the first quarter of 2012 compared to 10,742,182 common shares for the first quarter of 2011.

During the first quarter of 2012, AcelRx recognized revenue of $329,000 resulting from reimbursement for work completed under a research grant from the US Army Medical Research and Material Command, or USAMRMC, for development of its ARX-04 product candidate, a Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the quarter ended March 31, 2012 totaled $4.8 million, compared with $1.9 million for the quarter ended March 31, 2011.  The increase was primarily due to development expenses for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.  During the first quarter, AcelRx prepared for and initiated the first of three planned Phase 3 clinical trials, a randomized, double-blind, placebo-controlled efficacy and safety trial in adults with post-operative pain, following open-abdominal surgery.  In April 2012, AcelRx initiated the second ARX-01 Phase 3 study, a randomized, open-label, parallel-group comparison of the efficacy and safety of the Sufentanil NanoTab PCA System to the standard of care, IV PCA with morphine, in t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... Nov. 20, 2014  Market research firm Kalorama information says ... The Buy, in the medical device industry.  The firm ... will produce just 3% growth this year, which led ... of product lines and entrance by acquisition into new ... medical devices, The Global Market for Medical Devices, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... HONG KONG, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, ... acquire the remaining interests in the Group,s Chinese ... HK$90 million in shares.  Upon completion of the ...
... Calif., Feb. 24, 2011 Amgen (Nasdaq: AMGN ... 3 head-to-head trial that compared XGEVA ™ (denosumab) to ... skeletal-related events (SREs) in 1,901 men with prostate cancer and ... met its primary and secondary endpoints and demonstrated XGEVA,s superiority ...
Cached Medicine Technology:Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, ... dresses. “If you are looking for gorgeous beach wedding ... possible. Here you can enjoy 70% off discounts and ... a big marriage ceremony is the most important dream ... dress is uppermost priority. Ophelia, one of customers, said, ...
(Date:11/23/2014)... 2014 Syngenta lawsuits are now being ... farmers and agribusinesses that have allegedly incurred significant financial ... Viptera and Agrisure Duracade, genetically modified (GMO) corn ... sale in China. According to a report from Bloomberg ... U.S. corn imports. Because China is the third-largest American ...
(Date:11/22/2014)... Greenville, SC (PRWEB) November 23, 2014 ... back to their communities. AlignLife experience rapid growth in ... upon a very unique opportunity. AlignLife of Simpsonville ... area AlignLife offices for their first annual Toy Drive. ... local charity they would support with this year's toy ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has ... in order to prepare for the wedding season. All ... off. , UWDress.com is a reliable company that has ... the new items -- formal wedding guest attire. This new ... including superstar and princess. As one of the leading companies ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Today, Dylan ... its new collection of wedding dresses; the business offers ... other related accessories for ladies worldwide, allowing them to ... manager of the company, this new collection of chic ... launch. Moreover, they are offered at discounted rates now. ...
Breaking Medicine News(10 mins):Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2
... , sport-specific eyewear to prevent devastating injuriesAUSTIN, Texas, April 9 ... a routine basketball game his senior year of high school ... star who played years of hoops without any injuries. But ... teammate, Stephen ended up with a large laceration on his ...
... to prevent devastating injuriesOKLAHOMA CITY , April 9 ... game his senior year of high school turned into a ... years of hoops without any injuries. But when he was ... up with a large laceration on his left eyelid and ...
... IVF innovator introduces alternative to artificial insemination for less ... struggling to conceive a child usually have had but ... high-cost process of in vitro fertilization (IVF) ... intra-uterine insemination (IUI) , also known as ...
... an unapproved drug, one of 14 given recent warning, will ... (HealthDay News) -- Bowing to the pleas of hospice experts, ... intent to remove from the market an unapproved liquid morphine ... deputy director of the FDA,s Center for Drug Evaluation and ...
... Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts") announced today ... of the special dividend of $5.23 per share ... with Misys plc on October 10, 2008.(Logo: ... dividend, Allscripts disclosed that in general the special ...
... Effective Than Traditional Medical Care ALEXANDRIA, Va., April 9 ... of their readers with back pain, according to a ... 14,000 Americans who experience the condition. In the survey, ... treatment by medical specialists and primary care providers, a ...
Cached Medicine News:Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Eye Protection is Essential for Oklahoma Athletes 2Health News:Eye Protection is Essential for Oklahoma Athletes 3Health News:Fertility Docs Cut Costs of IVF Conception by 60 Percent 2Health News:FDA Reverses Stance on Removal of Morphine Painkiller 2Health News:Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008 2Health News:Consumer Reports Survey Shows High Satisfaction for Physical Therapist Treatment of Back Pain 2Health News:Consumer Reports Survey Shows High Satisfaction for Physical Therapist Treatment of Back Pain 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: